These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Reduction of nitric oxide with L-/NG-monomethyl arginine in interleukin-2 and anti-CD3 monoclonal antibody combination therapy.
    Author: Nakajima F, Asano T, Hayakawa M, Nakamura H.
    Journal: Int J Urol; 1996 Jan; 3(1 Suppl):S19-21. PubMed ID: 24304013.
    Abstract:
    We evaluated nitric oxide induction in antitumor therapy consisting of anti-CD3 monoclonal antibody (anti-CD3) and interleukin-2 (IL-2), then determined the effect of nitric oxide reduction with L-N(G)-monomethyl arginine (LNMA) on the therapeutic methods. Female C57BL/6 mice, MCA102 (a non immunogenic, NK-resistant murine fibrosarcoma cell line), and 145-2C11 (hamster anti-murine-CD3 mAb) were utilized in an experimental hepatic metastasis model developed by injecting a tumor cell suspension into the spleen of mice. A marked increase in serum NO2 (-) + NO1 was observed at 19 hours after anti-CD3 (10 μ, IV) and additional IL-2 administrations (40 × 10(1) U, twice, If) induced a further increase. The NO2, + NO3- elevation in spot urine in the combination therapy was not suppressed with LNMA at a dose of 100 μg/h but was significantly lowered at 300 μg/h. The efficacy of the anti-CD3 + IL-2 therapy was not diminished by LNMA administration either at 100 μg/h or at 300 μg/h.
    [Abstract] [Full Text] [Related] [New Search]